How to Get Jatenzo in North Carolina

What Jatenzo Is and Why It Matters for NC Patients

Jatenzo is the brand name for oral testosterone undecanoate, the first oral testosterone product approved by the FDA in the United States in many years. The FDA granted approval in March 2019 based on the TLANDO/Jatenzo clinical program (FDA label, NDA 210364). Its absorption depends on dietary fat, which is why the prescribing label requires it be taken with food containing at least 15 grams of fat at each dose.

How Oral Testosterone Undecanoate Differs from Injections and Gels

Unlike testosterone cypionate injections or topical gels, Jatenzo bypasses first-pass hepatic metabolism through lymphatic absorption. That distinction matters clinically because it avoids the liver toxicity historically associated with older oral 17-alpha-alkylated androgens such as methyltestosterone (FDA Drug Safety Communication, methyltestosterone). The tradeoff is a blood-pressure effect. Jatenzo's label carries a boxed warning for hypertension, and the key Swerdloff et al. Trial (J Clin Endocrinol Metab, 2020; N=166) found that 21% of participants required initiation or dose adjustment of antihypertensive therapy during the 52-week study period (Swerdloff et al., JCEM 2020).

Clinical Indication and Dosing

The approved indication is adult males with primary or hypogonadotropic hypogonadism. Dosing starts at 237 mg twice daily and is titrated based on mid-dose serum testosterone drawn 6 hours after the morning dose. The target range per the label is 300 to 1,050 ng/dL. Dose adjustments step in 79 mg increments (minimum 158 mg, maximum 396 mg per dose, twice daily). Patients who miss a meal should skip that dose rather than take a dose without adequate fat intake.

North Carolina Prescribing Rules for Jatenzo

Who Can Prescribe Jatenzo in NC

In North Carolina, Jatenzo may be prescribed by any licensed prescriber with DEA Schedule III authority. That includes MDs, DOs, and, under NC General Statute 90-18.1 and 90-18.2, nurse practitioners (NPs) and physician assistants (PAs) operating within their scope of practice and with appropriate supervisory agreements where required (NC Medical Board scope guidance). NPs practicing under full-practice authority per NC Session Law 2023 have independent prescribing rights that include controlled substances at Schedule III.

Telehealth Prescribing of Schedule III Controlled Substances in NC

North Carolina permits telehealth prescribing of Schedule III controlled substances when the prescriber holds an active NC medical license and a NC-registered DEA number. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires that at least one in-person medical evaluation precede the prescribing of a controlled substance via the internet (DEA Telemedicine FAQ). Temporary COVID-era DEA flexibilities extended the ability to prescribe controlled substances via telehealth without an in-person visit; as of mid-2025, DEA has extended those flexibilities while finalizing its Special Telemedicine Registration rule. Patients should verify current DEA policy with their provider before assuming a fully virtual path is available without any in-person component.

NC Medicaid Coverage Status

North Carolina Medicaid (NC Medicaid Managed Care) does not cover Jatenzo for the indication of male hypogonadism as of the 2025 NC Medicaid preferred drug list. Commercial insurance plans in NC vary widely. Most require prior authorization, and some exclude testosterone products categorized as "lifestyle" drugs. NC State Health Plan (for state employees) has covered compounded and brand testosterone with prior authorization in recent formulary years, though Jatenzo specifically may be placed on a non-preferred tier.

Getting a Jatenzo Prescription in North Carolina: Step-by-Step

Step 1: Confirm the Diagnosis with Required Labs

The Endocrine Society Clinical Practice Guideline (2018) recommends confirming hypogonadism with at least two morning serum total testosterone measurements below the laboratory's lower limit of normal, typically <300 ng/dL, collected on separate days (Endocrine Society Testosterone Guideline, 2018). The same guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations."

Required baseline labs before most NC providers or insurers will proceed include:

• Total testosterone (AM, 7 to 10 a.m.)
• LH and FSH (to classify primary vs. Secondary hypogonadism)
• Sex hormone-binding globulin (SHBG) and free testosterone (calculated or equilibrium dialysis)
• CBC with hematocrit
• PSA (in men 40 and older)
• Comprehensive metabolic panel
• Blood pressure measurement (mandatory given the Jatenzo boxed warning)

Step 2: Choose an In-Person or Telehealth Provider

North Carolina has several options. Board-certified endocrinologists and urologists at academic centers (UNC Health, Duke Health, Atrium Health Wake Forest Baptist) routinely manage hypogonadism. Wait times at academic centers for new patients can run 6 to 14 weeks. Telehealth platforms that hold NC DEA registrations can often schedule an initial visit within 48 to 72 hours and, if an in-person evaluation has already been completed, may proceed to prescribing on the same visit. Patients who have never had a controlled-substance evaluation in person should plan for at least one in-person encounter before telehealth-only prescribing of Jatenzo.

Step 3: Prior Authorization Submission

Most commercial payers in NC require prior authorization (PA) for Jatenzo. The PA packet typically requires:

• Two morning total-T values <300 ng/dL (copies of lab reports, not just provider notation)
• Documented symptoms consistent with hypogonadism (fatigue, decreased libido, erectile dysfunction, reduced muscle mass, mood changes)
• Failure of or clinical reason to avoid at least one preferred formulary testosterone product (usually testosterone cypionate injection or a generic gel)
• ICD-10 code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) where applicable
• Prescriber attestation that the patient has been counseled on the hypertension risk and that baseline blood pressure has been recorded

PA denials may be appealed with a peer-to-peer review between the prescribing clinician and the plan's medical director. The Swerdloff et al. 52-week key trial data (JCEM 2020) showing that 87% of treated patients achieved mean testosterone levels within the eugonadal range (300 to 1,050 ng/dL) provides strong clinical grounding for appeal letters.

Step 4: Pharmacy Dispensing in North Carolina

Jatenzo is dispensed through retail and specialty pharmacies. Major chains (CVS, Walgreens, Walmart, Harris Teeter) may stock or order it, though rural NC pharmacies sometimes require 2 to 5 business days to fulfill an initial order. Specialty pharmacies such as Optum Rx, CVS Specialty, and Walmart Specialty Pharmacy can ship to NC addresses. Manufacturer copay assistance through the Tolmar patient savings program may reduce out-of-pocket cost to as low as $0/month for commercially insured patients who qualify (Tolmar Patient Assistance).

For patients with no insurance coverage or denied PA, licensed 503A compounding pharmacies in North Carolina may compound oral testosterone undecanoate on a patient-specific prescription basis. Compounded preparations are not FDA-approved and differ from Jatenzo in formulation; bioavailability data for compounded oral testosterone undecanoate are limited compared with the proprietary lipid-based capsule formulation studied in the JCEM 2020 trial (Swerdloff et al., JCEM 2020). The North Carolina Board of Pharmacy maintains a list of licensed in-state compounding pharmacies at ncbop.org.

Monitoring Requirements After Starting Jatenzo in NC

Blood Pressure and Cardiovascular Monitoring

The FDA boxed warning for Jatenzo specifically calls out the risk of increases in blood pressure and adverse cardiovascular events. The prescribing label requires blood-pressure monitoring at each visit (FDA label, NDA 210364). The American Heart Association's 2023 scientific statement on testosterone and cardiovascular risk notes that patients receiving testosterone therapy should have blood pressure monitored at baseline, 3 months, and then every 6 to 12 months (AHA Scientific Statement, Circulation 2023).

Serum Testosterone Monitoring Schedule

Per the Jatenzo label, the first testosterone check occurs at steady state, typically 6 hours post-morning dose on day 7 or later. Dose titration continues until the mid-dose level falls between 300 and 1,050 ng/dL. Once stable, monitoring every 6 months is standard. The Endocrine Society's 2018 guideline recommends checking testosterone, hematocrit, and PSA at 3 to 6 months after initiation, then annually (Endocrine Society Guideline, JCEM 2018).

Hematocrit and PSA Surveillance

Testosterone therapy increases erythropoiesis. Hematocrit above 54% requires dose reduction or temporary discontinuation per standard clinical practice (Endocrine Society Guideline, JCEM 2018). PSA should be checked before initiation in men 40 years and older; a rise of more than 1.4 ng/mL within any 12-month period warrants urological evaluation per the Endocrine Society recommendation.

Lipid Panel Monitoring

Oral testosterone, like other androgen therapies, may reduce HDL cholesterol. The 52-week Swerdloff trial reported a mean HDL reduction of 7.9 mg/dL from baseline (Swerdloff et al., JCEM 2020). A fasting lipid panel at baseline and at 6 months is appropriate for most patients. Patients with pre-existing dyslipidemia or metabolic syndrome require closer follow-up per standard cardiovascular risk guidelines (ACC/AHA Cardiovascular Risk Guideline).

Transferring an Existing Jatenzo Prescription to North Carolina

Patients relocating to North Carolina who already have an active Jatenzo prescription from another state face several practical steps. North Carolina pharmacies can fill a prescription written by an out-of-state licensed prescriber for a Schedule III substance, provided the prescription meets NC pharmacy law requirements (quantity limits, prescriber DEA number, written or electronic format per 21 CFR 1306). However, most pharmacy benefit plans require that the dispensing pharmacy be in-network, and prior authorizations issued under a prior-state insurance plan do not automatically transfer.

The recommended sequence for relocating patients:

1. Obtain a copy of the most recent testosterone lab results and the active prior-authorization approval letter from the prior insurer.
2. Establish care with an NC-licensed prescriber (in-person or telehealth with valid NC DEA) within 90 days of relocation to avoid a gap in treatment.
3. Submit a new prior authorization to the NC-plan insurer using the prior approval letter and lab data as supporting documents.
4. If a gap in access is anticipated, the Tolmar patient assistance program can bridge supply for qualifying patients (Tolmar Patient Assistance).

The HealthRX Clinical Decision Framework for Jatenzo in NC

The HealthRX medical team applies the following five-gate framework when evaluating North Carolina patients for Jatenzo specifically (rather than other testosterone formulations):

Gate 1: Oral preference confirmed. The patient has documented adherence challenges with injections (needle phobia, travel schedule, no self-injection ability) or skin-contact concerns with topical gels (household members, skin conditions).

Gate 2: Hepatic and GI status reviewed. Severe hepatic impairment is a contraindication per the FDA label. Patients with inflammatory bowel disease or significant fat-malabsorption disorders may have erratic absorption from the lipid-dependent capsule.

Gate 3: Cardiovascular baseline acceptable. Uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg at baseline) should be managed before Jatenzo initiation given the boxed warning. Baseline blood pressure is documented at the prescribing visit.

Gate 4: Insurance pathway mapped. The prescriber's office has confirmed whether commercial, state, or no coverage applies, and has pre-identified the PA pathway or copay-assistance program before the prescription is transmitted.

Gate 5: Monitoring plan confirmed. The patient has a lab order placed for testosterone (6-hour post-morning dose), hematocrit, blood pressure, and PSA (if applicable) at the 6-to-8-week mark before leaving the initial visit.

Patients who meet all five gates are appropriate candidates for Jatenzo in the North Carolina clinical setting. Those who do not clear Gate 3 or Gate 2 may be better served by transdermal or injectable formulations until the underlying issue is resolved.

How Long Until Jatenzo Arrives in North Carolina

Timing from first clinical contact to capsule-in-hand varies by pathway:

• Telehealth with no in-person history required (if DEA flexibilities remain in effect): 48 to 96 hours for initial evaluation; add 2 to 5 business days for PA decision; add 1 to 5 business days for pharmacy fulfillment. Total: approximately 7 to 14 days.
• Telehealth after one in-person evaluation: Add 1 to 4 weeks for the in-person visit, then the same 7 to 14 day downstream timeline.
• Academic medical center (UNC, Duke, Atrium): New-patient wait of 6 to 14 weeks is common, after which the PA and pharmacy timelines above apply.
• PA denial and appeal: An appeal with peer-to-peer review adds 7 to 30 days depending on the insurer's turnaround requirement under NC insurance regulations.

Patients who pay cash or use the Tolmar savings card at a retail pharmacy skip the PA wait entirely. List price for a 30-day supply of Jatenzo (60 capsules at 237 mg) runs approximately $650, $850 without insurance. The Tolmar savings card has capped out-of-pocket cost at $0 for eligible commercially insured patients, per the program terms published at tolmarpatientassistance.com.

Special Populations and Considerations in North Carolina

Men with Obesity and Metabolic Syndrome

Obesity suppresses SHBG, which lowers total testosterone even when free testosterone is relatively preserved. NC obesity rates are above the national average at 36.4% of adults (CDC State Obesity Data, 2023), meaning a meaningful proportion of men presenting with low-T symptoms in NC may have functional hypogonadism secondary to obesity rather than true primary or secondary hypogonadism. The Endocrine Society guideline discourages testosterone therapy when hypogonadism is secondary to morbid obesity without first attempting weight reduction (Endocrine Society Guideline, JCEM 2018). For these patients, GLP-1 receptor agonist therapy (semaglutide or tirzepatide) to achieve weight loss may normalize testosterone without adding exogenous androgen.

Older Adults (Age 65 and Above)

The Testosterone Trials (TTrials, N=790, Snyder et al., NEJM 2016) examined testosterone therapy in symptomatic men 65 and older and found modest improvements in sexual function and bone density but raised questions about cardiovascular and prostate safety (Snyder et al., NEJM 2016). Jatenzo has not been studied specifically in the 65+ age group as a separate cohort. NC prescribers should apply conservative hematocrit targets and more frequent PSA monitoring in older adults.

Patients with Controlled Hypertension

Given Jatenzo's boxed warning, men with hypertension controlled on antihypertensive medication remain eligible if blood pressure is at goal (systolic <130 mmHg per AHA/ACC 2017 guidelines (AHA/ACC 2017 Hypertension Guideline)) at the time of prescribing. Blood pressure should be rechecked at 4 weeks after initiation and at every dose change.